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ABSTRACT 
Utilizing the Zebrafish Model to Determine Anti-Epileptic Properties of Mistletoe and 
Cannabis 
Epilepsy affects around 50 million people in the world, therefore improving 
treatment efficacy and safety for epileptics is imperative. In this study we sought to 
screen the effectiveness and safety of cannabis constituents (delta-9-tetrahydrocannabinol 
and cannabidiol) and Tapinanthus globiferus extracts in treating epilepsy. We used a 
zebrafish model wherein seizures were induced by treatment with pentylenetetrazol. Our 
results showed that Tapinanthus globiferus dose-dependently reduced seizure activity, 
and no toxicities were seen at the concentrations used. In contrast delta-9-
tetrahydrocannabinol and cannabidiol did not significantly reduce seizure activity and 
some toxicities were seen at the higher concentrations tested. We conclude that extracts of 
Tapinanthus globiferus show promise as anticonvulsants and further research is needed to 
identify the active constituents and their pharmacological properties. 
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1. INTRODUCTION 
1.1. Epilepsy 
 Epilepsy is a neurological condition that affects an estimated 50 million people 
worldwide and an estimated 2.4 million people are newly diagnosed each year (World 
Health Organization, 2017). It causes affected individuals to have seizures that can vary 
in frequency, duration and type. Causes of epilepsy include genetics, head trauma, brain 
conditions, certain infectious diseases, prenatal injury and certain developmental 
disorders. While some epilepsy causes are known, about half of the cases are idiopathic. 
Current treatments include medication, surgery, vagus nerve stimulation procedures and 
eating a ketogenic diet (Mayo Clinic, 2015). Pharmaceuticals, prescribed as a single 
medication or in combination with other medications, are the most common form of 
treatment for epilepsy and can have many side effects that increase in severity and 
incidence as more medications are used. Most people on anti-epileptic drugs will 
experience fatigue, dizziness, upset stomach and/or blurred vision. However, these drugs 
can cause much worse side effects, such as a decrease in cognitive function, bone loss, 
lowering white blood cell count, lowering platelet count, liver damage, pancreatic 
damage and rashes that cause skin to peel off (Schachter et al., 2013). 
 Dravet syndrome (DS) is a specific form of epilepsy that starts within the first 
year after being born and affects anywhere from 1:20,000 to 1:40,000 people. DS can 
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cause slowed mental and physical development, other neurologic conditions and 
musculoskeletal problems. By the age of 20, a person with DS has a mortality rate of 
20%. Around 80% of DS cases are due to a mutation of the SCN1A gene that causes 
impaired voltage-gated sodium channels (Escayg & Goldin, 2010). The frequent seizures 
caused by DS are prolonged (> 5 minutes) and can be triggered by a slight increase in 
temperature, vaccines, illness, excitation and/or certain light. These seizures are also very 
resistant to medications, and if a SCN1A mutation is present, then some of the common 
anti-epileptic drugs will worsen seizures if administered. Due to the resistant nature of 
DS, treatment generally requires a combination of medications. The combination that 
shows the most success is valproic acid, clobazam and stiripentol. Stiripentol, however, is 
not approved by the FDA (Welborn, 2015). Given the side-effects and lack of 
effectiveness of anti-epileptic drugs for some portions of epileptics, research should be 
conducted to find treatments for all types of epilepsy that have less adverse effects and 
reduce seizures more effectively. 
1.2. Cannabis 
 Delta-9-tetrahydrocannabinol (THC; Figure 1A) is a constituent of cannabis. It is 
psychoactive and is the reason for recreational cannabis abuse. In addition to its 
recreational use, it has uses as a therapeutic agent and is currently being utilized as an 
antiemetic and orexigenic pharmaceutical (Food & Drug Administration, 2004). THC can be 
produced synthetically or it can be extracted from the cannabis plant as an oil (Sharma, et 
al., 2012). 
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 Cannabidiol (CBD; Figure 1B) is another constituent of cannabis that is similar to 
THC in structure but is not psychoactive. While it does not have significant psychoactive 
properties, CBD has shown promise as a therapeutic agent for many different ailments in 
preliminary studies. These include use as an anti-epileptic, an anti-inflammatory, a 
neuroprotective agent, an analgesic, an anti-tumor agent, an anti-psychotic, an anxiolytic, 
and a substance abuse treatment (Volkow, 2015). CBD can also be extracted as an oil 
from cannabis or created synthetically. 
  
 
Cannabis use as a treatment for seizures is expanding but is hampered by its 
schedule I classification by the United States federal government. This means cannabis is 
not recognized as having an accepted medical use by the federal government, and it also 
makes research to determine its safety and effectiveness as a medicinal drug 
restricted(Drug Enforcement Administration, n.d.). However, 4 states plus D.C. allow 
recreational marijuana, 23 states allow medical marijuana, and 13 allow medical CBD, 
but the schedule I status of cannabis means that even in these states it can still be difficult 
to obtain the drug legally (Throckmorton, 2016). More research should be done on novel 
compounds to treat epilepsy so that effective and safe treatments can be more accessible 
Figure 1: (A) delta-9-tetrahydrocannabinol (THC) and (B) cannabidiol (CBD) 
(A) THC (B) CBD
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to all people. That includes providing sufficient research on cannabis that would 
determine its effectiveness, safety, and mechanism of action. Determining the mechanism 
of action for cannabis and its constituents will allow research for new compounds that 
have similar mechanisms for use as a treatment and will not be as difficult to obtain. 
1.3. Tapinanthus globiferus 
 Tapinanthus globiferus (TG) is a variety of mistletoe from the Loranthaceae 
family found in western Africa. It is a hemi-parasitic plant that grows on various types of 
trees such as the shea butter tree, the cocoa tree, the sweet orange tree, hog-plum tree, and 
rubber trees. These trees that TG uses as a host are economically valuable and so TG and 
the other African mistletoe varieties are seen as a nuisance by the farming community. 
While the farming community sees TG as a threat to their livelihood, it has beneficial 
applications as it has been traditionally used as a form of herbal medicine for multiple 
ailments including epilepsy, but there are no current publications on its effects on 
epilepsy (Adesina et al., 2013). A different variety of mistletoe (Viscum album), however, 
has been used by medical doctors to treat a patient with refractory childhood absence 
epilepsy, a drug-resistant version of epilepsy, and successfully eliminated her seizures 
(von Schoen-Angerer et al., 2015). As a traditional medicine, the leaves of TG are usually 
crushed up, soaked in either cold water or beer and then the liquid is consumed orally 
(Adesina, et al., 2013). Because TG has been used traditionally to treat epilepsy to some 
degree and other mistletoes have shown to be successful at treating epilepsy, we were 
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interested in determining which component of the plant is responsible for its anti-
convulsive properties. 
  1.4. Zebrafish as a model 
 Zebrafish (Danio rerio) are small fish from the Indian subcontinent that have been 
used as a model organism in research (Encyclopedia of Life, n.d.). They have a high 
fecundity, mature quickly, share a majority of their genome with humans, have embryos 
that develop outside of the parent organism and are easily observed under a microscope 
while developing (Burke, 2016). All of these characteristics help to make zebrafish an 
ideal candidate to be a research model. Furthermore, zebrafish have been shown to be an 
effective model in the areas of epilepsy, chemical toxicity and development (Baraban et 
al. 2005; Hill et al., 2005; Veldman & Lin, 2008). In addition to the ability to assess the 
behavioral aspects of the seizures in zebrafish via the ViewPoint Zebrabox, c-fos 
expression can be used to further confirm seizure activity. C-fos is a marker of neuronal 
activity that is transiently induced in neurons during seizures (Sagar et al., 1988; 
Dragunow and Robertson, 1988; Kiessling and Gass, 1993). Zebrafish can also be used as 
a model that mimics DS by performing a SCN1A gene knockdown (Rosen et al., 2009). 
The knockdown is performed using a morpholino that is antisense complementary to the 
SCN1A gene. The morpholino is introduced to zebrafish embryos using microinjection. 
This DS model has been used to identify both fenfluramine and clemizole as a promising 
drug to treat this form of epilepsy (Zhang et al., 2015; Baraban et al., 2013). 
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1.5. Study Goals 
 In this study, we utilize the zebrafish model to address our three main goals. The 
first is to identify novel natural compounds that effectively reduce seizures; diazepam 
will be used as a reference drug to compare efficacy. The second is to determine the 
changes in gene expression associated with exposure to THC, CBD, or TG extracts. The 
third is to evaluate THC, CBD and TG extracts for developmental toxicities. We 
hypothesize that one or more of these compounds will show anticonvulsant properties 
(e.g. decreased large activity and c-fos gene expression) without causing overt toxicity. 
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2.  METHODS AND MATERIALS 
2.1. Zebrafish culture and egg collection 
 AB line wild-type zebrafish were purchased from Zebrafish International 
Resource Center (ZFIN, Eugene, OR) and raised under the approved IACUC protocol. 
The zebrafish were kept in the Aquatic Habitats ZF0601 Zebrafish Stand-Alone System 
(Aquatic Habitats, Apopka, FL) with each unit containing ~0.3 L of water per fish. The 
habitats contained zebrafish appropriate water (pH 7.0-7.6, 340 parts per million (ppm) 
Instant Ocean, Cincinnati, OH) in a climate (25-28°C) and light (14 hours of light and 10 
hours of dark) controlled room. They were fed Gemma Micro 300 (Skretting Nutreco 
Company, Westbrook, ME) two times every day. The fish used for breeding did not have 
disease and were also of a healthy breeding age (4-18 months post fertilization). To 
prepare for egg collection, the fish were transferred to breeding tanks at a 1:1 ratio of 
males to females and were then left overnight to produce fertilized eggs. 
 After the lights turned on the following morning, fish were returned to their 
normal holding tanks. The eggs that had fallen through the protective grate to the bottom 
of the breeding tank were then collected by pouring the water from the breeding tanks 
through a sieve. The breeding tanks were rinsed and that water was then sieved again to 
ensure that every egg had been collected.  
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 Unwanted debris and unfertilized/dead eggs were removed using a transfer pipette 
from the collected eggs. The cleaned eggs were then transferred to a petri dish containing 
zebrafish water (60 ppm Instant Ocean, pH 7.5) and placed in an incubator at 28°C for 5 
days. Dead eggs were removed daily. 
2.2. Exposure procedures 
 At 120 hours post fertilization (hpf), the larvae were transferred to 96 well plates 
with one larva in each well. The larvae were chosen based on lack of deformities and the 
presence of an inflated swim bladder. The water in each well was removed and replaced 
with 150 µL of a dosing solution. TG extracts were provided from Dr. Jordan Zjawiony. 
CBD and THC were obtained from NIDA Drug Supply Program. The zebrafish (n=12/
treatment/plate; 3 plates/treatment) were exposed to: control (0.05% DMSO), extracts 
from TG (0.008, 0.04, 0.2, 1, or 5 mg/L), THC (0.02, 0.09, 0.45, 2.23, or 11.2 µM) or 
CBD (0.003, 0.012, 0.06, 0.32, or 1.59 µM) and 25 µM (7 mg/L) diazepam (DZP). TG 
extracts that were tested were AF-Hx, AF-H2O, AF-Bu, AF.1.10.TG.9, AF.1.10.TG.14, 
AF.1.16.TG.8, AF.1.14.TG.4, AF.1.16.TG.3, AF.1.14.TG.2, AF.1.10.TG.3, AF.1.2.TG.2 
H2O/MeOH, AF.1.2.TG.2 MeOH, AF.1.2.TG.2 ACE, AF.1.2.TG.2 CHCl3. Once the 
dosing was complete, the plates were placed back into the incubator and lightly covered 
with aluminum foil to protect the compounds from the light. 
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2.3. Seizure induction 
 Following a 24 hour exposure to the dosing solutions, the larvae were observed to 
determine if TG, THC, or CBD had any toxic side effects: a lack of response to touch, 
pericardial edema, yolk sac edema, a curved body axis and/or a non-inflated swim 
bladder. If any of these signs of toxicity were observed, then that larva was excluded 
from further analysis. To induce seizures, 50 µL of 20 mM pentylenetetrazol (PTZ;Sigma 
Aldrich) was added to each well, except for the first row which was the control, to yield a 
final concentration of 5 mM PTZ.  
2.4. Viewpoint data collection and analysis 
 Following the addition of PTZ to induce seizures, the plate is placed in the 
ViewPoint ZebraBox and the larvae are acclimated for 5 minutes before behavior 
recording. The ViewPoint ZebraBox tracks larval movement for 15 minutes with the 
lights on at 100% with a threshold of 27 and small and large activity parameters set at 5-9 
and >9 mm/s, respectively. The ZebraBox software creates an excel sheet that includes 
the duration each larva spends in the inactive, small, and large movements over the 15 
minute duration. Movement that meets the large activity requirements is indicative of 
seizure activity and was the data that was used to test for a compound’s effectiveness as 
an anticonvulsant. Therefore, PTZ significantly increases the duration of large activity 
compared to control and a compound with anticonvulsant properties would significantly 
decrease the PTZ-induced large activity compared to PTZ alone and ideally would not be 
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significantly increased compared to control. Larvae were then euthanized with buffered 
MS-222, placed in RNAlater and stored at -80°C  
 The data collected from the ViewPoint ZebraBox was analyzed using GraphPad 
Prism 5.0 (La Jolla, CA). The data sets were first checked for normality using a 
Kolmogorov-Smirnov test. If the data passes the Kolmogorov-Smirnov test for normality, 
then statistically significant differences compared to PTZ was determined using a t-test. If 
the data did not pass the Kolmogorov-Smirnov test for normality, then a Mann-Whitney 
test was used for analysis. All tests used p ≤ 0.05 for determination of statistical 
significance (n=22-36 larva/treatment). Each data set is given as the mean ± the standard 
error. 
2.5. RNA extraction, reverse transcription and qPCR  
 To determine changes in gene expression caused by the addition of the 
compounds, the mRNA expression of c-fos (higher expression is associated with more 
epileptic activity) is measured using qPCR. The RNA was isolated using TRIzol 
(Ambion) and then purified by using an RNeasy Mini Kit (Qiagen) according to 
manufacturer’s protocol. The purified RNA collected was reverse transcribed to cDNA 
using TaqMan Reverse Transcription reagents (Applied Biosystems). The abundance of 
c-fos gene expression was normalized to 18S housekeeping gene expression and 
determined using qPCR with SYBR Green in a GeneAmp 7500 Sequence Detection 
System (Applied Biosystems). The primers used in this qPCR are c-fos forward: 5'-CAC 
CGA TAC ACT GCA AGC TGA A-3’, c-fos reverse: 5'-CAG GTT GGC GAT GTC GTT 
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CT-3’, 18S forward: 5'-TGG TTA ATT CCG ATA ACG AAC GA-3’, 18S reverse: 5'-
CGC CAC TTG TCC CTC TAA GAA-3’ (Corrales et al., 2014a). Amplification 
efficiencies of c-fos and 18s were determined using the formula E = 10 ^ (-1/slope) - 1 
and were between the accepted range of 78-106% (Higuchi et al., 1993). The linearized 
2–∆Ct values from the qPCR were analyzed using a t-test (p<0.05; n=3 pools/treatment; 
10-12 larva/pool) and fold change relative to control was plotted (2–∆∆Ct). 
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3. RESULTS 
 3.1. Large activity post-PTZ exposure
 The results for THC are shown in Figure 2A. None of the THC concentrations 
tested showed a significant decrease in large movement compared to 5 mM PTZ. The 
results for CBD are shown in Figure 2B. None of the CBD concentrations tested showed 
a significant decrease in large movement compared to 5 mM PTZ. 
 
  
Figure 2: THC (a) and CBD (b) seizure activity. Zebrafish larval behavior was 
analyzed using the Viewpoint Zebrabox (15 min recording with 100% light) to record 
duration of large activity (> 9mm/sec), following a 24 hr exposure (120-144 hpf) to 
natural compounds, induced by 5 mM PTZ to determine if these natural compounds 
have anticonvulsant properties (n=29-35 per treatment; Student t-test; p≤0.05).
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 Eleven different fractions of TG extracts were tested and two of these fractions 
(AF.1.10.TG.9 and AF.1.10.TG.14) showed a significant decrease in large movement 
compared to 5 mM PTZ. Figure 3A shows that AF.1.10.TG.9 significantly decreased 
large movement in both the 1 and 5 mg/L concentrations by 29 and 41%, respectively, 
compared to PTZ alone. Figure 3B shows that AF.1.10.TG.14 significantly decreased 
large movement in the 5 mg/L concentration by 22% compared to PTZ alone. The 1 mg/L 
concentration for AF.1.10.TG.14 was almost statistically significant as well. 
AF.1.16.TG.8, AF.1.14.TG.4, AF.1.16.TG.3, AF.1.14.TG.2, AF.1.10.TG.3, AF.1.2.TG.2 
H2O/MeOH, AF.1.2.TG.2 MeOH, AF.1.2.TG.2 ACE, AF.1.2.TG.2 CHCl3 extracts from 
Figure 3: AF.1.10.TG.9 (a) and AF.1.10.TG.14 (b) seizure activity. Zebrafish larval behavior 
was analyzed using the Viewpoint Zebrabox (15 min recording with 100% light) to 
record duration of large activity (> 9mm/sec), following a 24 hr exposure (120-144 hpf) 
to natural compounds, induced by 5 mM PTZ to determine if these natural compounds 
have anticonvulsant properties (n=22-36 per treatment; Student t-test; p≤0.05).
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TG did not show any significant differences from PTZ. AF.16.TG.3 data is shown in 
Figure 4 as an example of one of the fractions that did not show anticonvulsant activity.  
 3.2. Gene Expression 
 Expression of the c-fos gene as determined by qPCR was performed for 
AF.1.10.TG.9. The results are shown in Figure 5 expressed as the fold increase compared 
to the control group. PTZ did significantly induce c-fos expression as compared to 
control. However, there were no significant differences in expression between PTZ only 
and the treatment groups. We hypothesized a reduction in the 1 and 5 mg/L AF.1.10.TG.9 
and DZP groups, but there was actually a slight increase. Expression of c-fos was also 
Figure 4: AF.1.16.TG.3 seizure activity. Zebrafish larval behavior was analyzed using the 
Viewpoint Zebrabox (15 min recording with 100% light) to record duration of large 
activity (> 9mm/sec), following a 24 hr exposure (120-144 hpf) to natural compounds, 
induced by 5 mM PTZ to determine if these natural compounds have anticonvulsant 
properties (n=28-35 per treatment; Student t-test; p≤0.05).
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determined for both CBD and THC. The results in Figure 6 show a dose-dependent 
increase in c-fos expression for both THC and CBD. 
 
Figure 5: AF.1.10.TG.9 c-fos expression. Expression of c-fos was determined by 
qPCR for each dosing group of the zebrafish larvae. The p-value above each bar 
shows that group compared to control using a Student t-test. (p≤0.05; n=3 pools/
treatment; 10-12 larvae/pool)
Figure 6: THC (a) and CBD (b) c-fos expression. Expression of c-fos was determined by qPCR for each 
dosing group of the zebrafish larvae. The p-value above each bar shows that group compared to control 
and the p-value above the horizontal bars shows that group compared to PTZ using a Student t-test. 
(p≤0.05; n=3 pools/treatment; 10-12 larvae/pool) 
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3.3. Toxicity 
 Figure 7 shows examples of deformities that are indicative of exposure to a toxic 
substance including pericardial edema, yolk sac edema, non-inflated swim bladder, etc. 
Figure 8A shows that CBD had a low incidence of mortality and physical deformities, 
however, at 1.59 µM it caused abnormal, erratic swimming patterns. Figure 8B shows 
that THC had a very high incidence of mortality at the 11.2 µM concentration. THC had a 
low incidence of erratic swimming and physical deformities. None of the compounds 
from TG showed toxicity at any concentration tested. 
 
Figure 7: Zebrafish morphology. A normal zebrafish is shown in A and B along with labels to 
show what areas are observed for deformity. The left picture in C shows a close lateral view of 
a normal zebrafish while the right picture shows a close lateral view of a deformed zebrafish 
with deformities labeled. Any significant deviation from A and B is considered a deformity that 
is indicative of toxicity. (Corrales et al., 2014b)
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Figure 8: CBD (a) and THC (b) toxicity. Zebrafish larvae were given different 
concentrations of either CBD (0.003, 0.012, 0.06, 0.32, 1.59 µM), THC (0.02, 0.09, 
0.45, 2.23, 11.2 µM), DZP (25 µM), or weren’t given any drug as a control group. 
Larvae were checked for signs of toxicity following the dosing. n=24-52
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4. DISCUSSION
 The goal of this study was to use zebrafish to screen a series of compounds and 
extracts for anti-seizure activity. Compounds or extracts that are effective may ultimately 
prove to be useful in the treatment of epilepsy. We hypothesized that cannabinoids or 
mistletoe extracts would have anticonvulsant properties. However, the two compounds 
tested from cannabis, CBD and THC, did not show much promise in reducing PTZ-
induced seizures according to the View Point data. Cannabinoids have shown mixed 
results in treating generalized seizures in other animal studies (Devinsky, et al., 2014). 
This could possibly be due to different experimental designs such as length of treatment 
and the variety of routes of administration in these studies. There is anecdotal evidence 
that THC and CBD are useful in people who suffer from DS and other similar forms of 
drug resistant epilepsy. The seizure induction trials in this study used a zebrafish model 
that utilized PTZ to induce seizures that represent a general form of epilepsy. This model 
does not represent the DS class of seizures, so while THC and CBD did not look like a 
viable seizure treatment in this study for general seizures, further research should be done 
with zebrafish DS models to determine their effects on this specific type of epilepsy 
(Gupta, 2013). 
 In contrast to the cannabis compounds, the results from the activity monitoring for 
TG showed that two of the eleven extract fractions could be useful in reducing seizures. 
AF.1.10.TG.9 appeared to be the more effective of these two fractions; it reduced PTZ-
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induced seizure activity at the 1 and 5 mg/L concentration. AF.1.10.TG.14 only showed 
significant reduction at the 5 mg/L concentration; however, 1 mg/L had a p value of 
0.051. It is possible that if more trials are done that the 1 mg/L concentration would reach 
statistical significance. While no studies have been done specifically on TG for epilepsy, 
there are reports with different varieties of African mistletoe that have suggested anti-
seizure activity. Tapinanthus dodoneifolius completely eliminates PTZ-induced seizures 
in Wistar rats at a dose of 500 mg/kg methanolic leaf extract (Uthman et al., 2015). A 
methanol extract from the stem of Viscum capense also reduced PTZ-induced seizures in 
albino mice at concentrations of 50-100 mg/kg (Amabeoku et al., 1998). Globimetula 
braunii extract prevented PTZ seizures in 83.33% of the mice given 150 mg/kg of an 
ethyl acetate fraction (Aliyu et al., 2014). This suggests that there may be a similar 
compound in all of these different varieties of mistletoe that causes a dose-dependent 
reduction in seizures. If the hypothesized similar compound could be identified and 
isolated in mistletoe, then it could possibly be even more effective and/or synthetically 
replicated. These studies also support that the dose of the TG extracts should be increased 
in future trials to see if higher concentrations will continue to show a greater reduction. 
 Gene expression analysis was performed on the most promising potential 
therapeutic from TG (AF.1.10.TG.9), THC, and CBD. The expression of c-fos in the 
brain is hypothetically indicative of seizure activity, so if seizures increase or decrease, 
c-fos expression should as well (Baraban et al., 2005). Our results showed an unexpected 
dose-dependent increase in c-fos expression for all three of the compounds. While THC 
and CBD did not show any seizure reduction, AF.1.10.TG.9 did. Therefore, we 
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hypothesized to, but did not see, a dose-dependent decrease in c-fos expression for 
AF.1.10.TG.9. However, we did not measure the c-fos expression of just the brains of the 
larvae, but a pool of 10-12 whole larvae (only three biological replicates; n=3). It could 
be that AF.1.10.TG.9 did decrease c-fos expression in the brain, but this was masked by 
increased expression in the other tissues. Also, c-fos gene expression has been shown to 
increase with administration of other forms of anesthesia in rats, so the MS-222 might 
have affected the results as well (Bullitt, 1990). All treatment groups did receive the same 
amount of anesthesia, so any overall increase should be the same for each group reducing 
its significance. Future studies should be done with AF.1.10.TG.9 in larger animal models 
so that changes in c-fos expression of the brain alone can be measured or by in situ 
hybridization whole mounts on individual zebrafish larvae. 
 Another advantage of the zebrafish assay is that toxicity can be assessed on each 
organism prior to behavioral analysis. The highest THC concentration of 11.2 µM caused 
death in over half of the zebrafish, but the rates of other deformities remained fairly low 
at concentrations between 0.02 and 2.23 µM. In contrast, CBD caused less than 10% of 
death or physical deformities at any of the concentrations tested. It did, however, cause 
25% of the zebrafish to engage in abnormal swimming patterns at 1.59 µM. The reason 
for the erratic swimming is not clear, but it could due to an adverse interaction with the 
nervous systems and the signals to the musculature or with the musculature directly. This 
is consistent with research that links marijuana with adverse effects on brain development 
and physical deformation (Thomas, 1975;Volkow et al., 2014). THC has also been shown 
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to be lethal to Fischer rats in high enough doses but the toxic concentration varies 
depending on the route of administration (Rosenkrantz et al., 1974). 
 Importantly for future drug development, TG did not show any toxicities or 
adverse effects at the concentrations tested. This result is very significant in that the most 
ideal treatment would cause minimal side effects. Further testing should be done to 
determine the highest concentrations of TG extracts that can be considered safe. 
Additionally, longer term exposures should be conducted to determine if acute or chronic 
exposures cause toxicities. 
 The overall results from this study indicate that TG could be a potential source of 
effective treatment for epilepsy that may be less likely to cause side effects and toxicities. 
While cannabis did not show any effectiveness for treating general seizures in this study, 
further studies should be conducted utilizing a DS model to determine its efficacy in 
reducing drug-resistant epilepsy seizures. TG could potentially be useful in treating drug-
resistant varieties of epilepsy as well, so further research using DS models should be 
conducted. 
 Because AF.1.10.TG.9 was not toxic at the highest concentration tested and PTZ-
induced seizure activity was not reduced completely to control levels, higher 
concentrations of this extract should be tested and may be more effective. Furthermore, 
chemical analysis of the constituents of this fraction can be determined. Individual 
chemicals of the extract can then be tested and may prove to be more effective alone than 
the AF.1.10.TG.9 mixture. If these compounds are deemed effective and safe, then they 
should be scaled up to mammal trials and eventually epilepsy clinical trials.  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